{"id":"f-627","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"F-627 is a pegylated G-CSF receptor agonist designed to provide sustained neutrophil support with less frequent dosing than conventional G-CSF. It binds to and activates the G-CSF receptor on hematopoietic progenitor cells, promoting their differentiation and proliferation into mature neutrophils, thereby reducing chemotherapy-induced neutropenia and related infections.","oneSentence":"F-627 is a long-acting granulocyte colony-stimulating factor (G-CSF) analog that stimulates neutrophil production and mobilization.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:45.345Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia (CIN) in patients with cancer receiving myelosuppressive chemotherapy"}]},"trialDetails":[{"nctId":"NCT04174599","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of F-627 and GRAN®","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2018-04-12","conditions":"Breast Cancer, Neutropenia","enrollment":242},{"nctId":"NCT02527746","phase":"PHASE1","title":"Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2012-12","conditions":"Neutropenia, Breast Cancer","enrollment":18},{"nctId":"NCT06134765","phase":"PHASE2","title":"Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-11-30","conditions":"Colorectal Cancer, Pancreatic Cancer","enrollment":89},{"nctId":"NCT03252431","phase":"PHASE3","title":"Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2018-04-12","conditions":"Breast Cancer, Neutropenia","enrollment":393},{"nctId":"NCT02872103","phase":"PHASE3","title":"Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2016-08","conditions":"Breast Cancer, Neutropenia","enrollment":122},{"nctId":"NCT02522234","phase":"PHASE1, PHASE2","title":"A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2014-02-25","conditions":"Neutropenia","enrollment":15},{"nctId":"NCT01648322","phase":"PHASE2","title":"Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2012-06","conditions":"Breast Cancer, Neutropenia","enrollment":232},{"nctId":"NCT02521441","phase":"PHASE2","title":"A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2014-07-03","conditions":"Neutropenia","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant Human Granulocyte Colony Stimulating Factor (rh G-CSF) Fc fusion protein","Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein"],"phase":"phase_3","status":"active","brandName":"F-627","genericName":"F-627","companyName":"EVIVE Biotechnology","companyId":"evive-biotechnology","modality":"Biologic","firstApprovalDate":"","aiSummary":"F-627 is a long-acting granulocyte colony-stimulating factor (G-CSF) analog that stimulates neutrophil production and mobilization. Used for Chemotherapy-induced neutropenia (CIN) in patients with cancer receiving myelosuppressive chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}